The ophthalmic drugs market in Italy is expected to reach a projected revenue of US$ 2,953.2 million by 2033. A compound annual growth rate of 8.3% is expected of Italy ophthalmic drugs market from 2026 to 2033.
Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc
Other key industry trends
In terms of revenue, Italy accounted for 3.8% of the global ophthalmic drugs market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany ophthalmic drugs market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 3,586.1 million by 2033.
Higher access to innovative diagnostic procedures and therapeutic approaches due to high healthcare expenditure and favorable reimbursement policies are supporting market growth in Italy. The healthcare system in the country is well-established, and this creates an opportunity for novel products to enter the market and fulfill unmet needs.
Increasing awareness about these disorders is estimated to boost the market. For instance, The International Agency for the Prevention of Blindness (IAPB) Italy promoted World Glaucoma Week in 2018. The IAPB is an alliance of corporations, civil society organizations, and professional bodies that promote eye health.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Ophthalmic Drugs Market Outlook will help companies and investors design strategic landscapes.
Anti-Vegf Agents was the largest segment with a revenue share of 38.79% in 2025.
Horizon Databook has segmented the Italy ophthalmic drugs market based on anti-vegf agents, anti-glaucoma, anti-inflammatory, anti-allergy, gene & cell therapy covering the revenue growth of each sub-segment from 2021 to 2033.
Higher access to innovative diagnostic procedures and therapeutic approaches due to high healthcare expenditure and favorable reimbursement policies are supporting market growth in Italy. The healthcare system in the country is well-established, and this creates an opportunity for novel products to enter the market and fulfill unmet needs.
Increasing awareness about these disorders is estimated to boost the market. For instance, The International Agency for the Prevention of Blindness (IAPB) Italy promoted World Glaucoma Week in 2018. The IAPB is an alliance of corporations, civil society organizations, and professional bodies that promote eye health.
Italy Ophthalmic Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
Anti-Allergy
Anti-VEGF agents
Anti-glaucoma
Gene & Cell Therapy
Others
Anti-inflammatory
Italy Ophthalmic Drugs Market Disease Outlook (Revenue, USD Million , 2021-2033)
Dry Eye
Allergies
Glaucoma
Infection
Retinal Disorders
Uveitis
Others
Italy Ophthalmic Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Topical
Systemic
Local Ocular
Italy Ophthalmic Drugs Market Dosage Type Outlook (Revenue, USD Million , 2021-2033)
Gels
Eye solutions & suspensions
Capsules & Tablets
Eye drops
Ointments
Italy Ophthalmic Drugs Market Product Type Outlook (Revenue, USD Million , 2021-2033)
OTC drugs
Prescription
Italy Ophthalmic Drugs Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
Branded Drugs
Generic Drugs
Reasons to subscribe to Ophthalmic Drugs Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Ophthalmic Drugs Market Outlook databook
Our clientele includes a mix of Ophthalmic Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy Ophthalmic Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Italy Ophthalmic Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.